SERD Combination Slows Breast Cancer After CDK4/6 Inhibitor Progression
(MedPage Today) -- An all-oral treatment regimen for advanced estrogen receptor (ER)-positive breast cancer almost doubled progression-free survival (PFS) versus standard endocrine therapy in a study of post-CDK4/6 progression disease. Among patients...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.
